Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px
Collaboration › Details

Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck

 

Period Period 2017-01-12
Organisation Partner, 1st Merck KGaA
  Group Merck (DE) (Group)
Products Product data integration and analysis s/w (general)
  Product 2 artificial intelligence (AI) / machine learning
     

Merck KGaA. (1/12/17). "Press Release: Merck and Palantir Launch New Healthcare Acceleration Partnership". Palo Alto, CA & Darmstadt.

> Collaboration of big data-driven initiatives

> Partners seek to revolutionize delivery of patient services


Merck, a leading science and technology company, today announced a partnership with Palantir, developer of the world’s most sophisticated data integration and analysis software, at Palantir’s headquarters in Palo Alto, California. The partnership will leverage Palantir’s advanced data analytics capabilities to help Merck better and more rapidly develop and deliver medicines to patients, commercialize new products, and improve patient outcomes. Initially Merck will apply Palantir’s technology to cancer treatment and patient services. Ultimately Merck plans to deploy Palantir’s technology across all three of the company’s business sectors Healthcare, Life Science and Performance Materials. Financial details were not disclosed.

“As a science and technology company, we are tackling the greatest challenges in healthcare, life science and performance materials. Now we are teaming up with Palantir since developing breakthrough technologies requires superior data analytics capabilities, and Palantir optimally complements our skills in that respect,” said Stefan Oschmann , Chairman of the Executive Board and CEO of Merck during the announcement of this partnership on Thursday.

“At the heart of Palantir’s mission is the desire to bring new tools to solve the world’s most difficult problems,” said Alexander Karp, founder and CEO of Palantir. “When something like cancer is killing 8.2 million people each year, we want to do everything we can to apply our technological expertise to the fight, alongside partners who have been there since the beginning. We are pleased to have found a partner that shares our values and vision.”

The partnership will launch with three initiatives within the Healthcare business sector of Merck.

· Medical Research & Drug Development: The partnership will increase precision of the drug development process by developing a collaborative data and analytics platform so that Merck researchers can analyze real-world and bioinformatics data to understand the patients who may benefit most.

· Global Patient Intimacy: The partnership will improve the experience of patients using Merck products by utilizing large-scale data sources to increase adherence and understand real-world drug efficacy.

· Global Supply Chain: Merck and Palantir’s data and analytics platform will improve supply chain forecasting and agility in order to provide medicines to patients around the world with maximum speed and reliability.

Biomedical research generates unprecedented volumes of rapidly evolving data every day. But accessing, learning from, and expanding on those assets has become a huge bottleneck in scientists’ ability to bring new innovations from the bench to the bedside. Through their combined expertise, Merck and Palantir will aim to harness the power locked inside that data for the benefit of patients.


Palantir

Palantir Technologies is a leading data integration platform. Palantir‘s software products are currently deployed by financial institutions, NGO’s, government agencies and other organizations to solve mission critical data driven problems in intelligence, defense, law enforcement, data protection, health care and global finance among other areas. Palantir’s platofrm is built to manage sensitive information while giving institutions the tools to effectively protect privacy.

Palantir is headquartered in Palo Alto, Calif. Additional information is available at www.palantir.com


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

   
Record changed: 2019-05-01

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top